deflazacort has been researched along with Cataract in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horn, PS; Rice, ML; Wong, B; Yang, MB | 1 |
| Alman, BA; Biggar, WD; Mayo, AL; McAdam, LC | 1 |
| Alman, B; Biggar, WD; Comi, LI; Harris, VA; Nigro, G; Palladino, A; Passamano, L; Politano, L; Vajsar, J | 1 |
| Alman, B; Biggar, WD; Eliasoph, L; Harris, VA | 1 |
| Bérubé, D; Brousseau, Y; D'Arcy, S; Dubé, J; Filiatrault, M; Fournier, A; Houde, S; Lapierre, G; Vanasse, M | 1 |
| Ferraris, JR; Krmar, RT; Ramirez, JA; Torres, CG | 1 |
| Biggar, WD; Fehlings, DL; Gingras, M; Harris, VA; Steele, CA | 1 |
2 trial(s) available for deflazacort and Cataract
| Article | Year |
|---|---|
Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Topics: Adolescent; Body Height; Body Weight; Calcium; Case-Control Studies; Cataract; Child; Clinical Protocols; Dietary Supplements; Drug Administration Schedule; Follow-Up Studies; Fractures, Bone; Humans; Immunosuppressive Agents; Male; Motor Activity; Muscular Dystrophy, Duchenne; Pregnenediones; Psychomotor Performance; Scoliosis; Treatment Outcome; Vitamin D | 2004 |
Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Body Height; Body Weight; Bone Density; Cataract; Fractures, Bone; Humans; Longitudinal Studies; Male; Muscular Dystrophy, Duchenne; Pregnenediones; Scoliosis; Treatment Outcome | 2008 |
5 other study(ies) available for deflazacort and Cataract
| Article | Year |
|---|---|
Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.
Topics: Adolescent; Cataract; Cataract Extraction; Child; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Intraocular Pressure; Male; Muscular Dystrophy, Duchenne; Ocular Hypertension; Prednisone; Pregnenediones; Prevalence; Retrospective Studies; Time Factors; Tonometry, Ocular; Young Adult | 2018 |
The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
Topics: Adolescent; Adrenal Cortex Hormones; Body Height; Bone Density; Canada; Cataract; Child; Fractures, Bone; Humans; Immunosuppressive Agents; Male; Muscle Strength; Muscular Dystrophy, Duchenne; Pregnenediones; Spinal Injuries; Spine; Walking; Weight Gain | 2012 |
Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
Topics: Adolescent; Body Height; Body Weight; Cataract; Child; Humans; Immunosuppressive Agents; Lung; Male; Motor Activity; Muscular Dystrophy, Duchenne; Posture; Pregnenediones; Quality of Life; Respiratory Function Tests; Retrospective Studies; Stroke Volume; Treatment Outcome; Walking | 2006 |
Posterior subcapsular cataracts associated with deflazacort therapy.
Topics: Anti-Inflammatory Agents; Cataract; Child; Female; Humans; Pregnenediones | 1997 |
Deflazacort treatment of Duchenne muscular dystrophy.
Topics: Activities of Daily Living; Adolescent; Anti-Inflammatory Agents; Body Height; Body Weight; Cataract; Child; Humans; Male; Motor Skills; Muscular Dystrophy, Duchenne; Pregnenediones; Retrospective Studies; Treatment Outcome; Vital Capacity; Walking | 2001 |